Browse studies

Find your next paid study

5 recruiting studies matching your filters

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outc…

Prurigo Nodularis

Estimated

~$10 – $1,125

Galderma R&DNCT06988618

Phase 2

Evaluating the Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients: A 24-Week Study

The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).

Prurigo Nodularis (PN)

Estimated

~$10 – $6,250

University of Maryland, BaltimoreNCT07620561

Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)

Prurigo Nodularis (PN)

Estimated

~$10 – $8,750

Beijing InnoCare Pharma Tech Co., Ltd.NCT07236099

Phase 3

A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: * Screening period: 2 to 4 weeks. * Treatmen…

A 24 Week, Open-Label Study to Evaluate the Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Prurigo Nodularis

A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.

Prurigo Nodularis

Estimated

~$10 – $7,500

Psoriasis Treatment Center of Central New JerseyNCT06773403